¥È¥Ã¥×
|
²ñ¼Ò³µÍ×
|
¶È̳ÈÏ°Ï
|
ÆÈÆäÊËÝÌõÉô
|
ÉʼÁÊݾÚ
|
À®¸ùÎã
|
ºÎÍѾðÊó
|
¤ªÌ䤤¹ç¤ï¤»
¶È̳ÈÏ°Ï
 
´ðÁðå³Ø¤ÈÎ×¾² ¾Ü¤·¤¯

À¸Íý³Ø¡¢ÉÂÍý³Ø¡¢À¸Êª²½³Ø¡¢Ê¬»ÒÀ¸Êª³Ø¡¢¥Ð¥¤¥ª°å³Ø¹©Äø¡¢½Û´Ä´ïÆâ²Ê¡¢¸ÆµÛ´ïÆâ²Ê¡¢Ç¾³°²Ê¡¢¿À·Ð³°²Ê...

 
Ìô³Ø»ñÎÁ ¾Ü¤·¤¯

ÌôÍý³Ø¡¢ÆÇÍý³Ø¡¢ÌôÉʲ½³Ø¡¢ÌôÉÊʬÀϳء¢ÌôºÞ³Ø¡¢À½ºÞ½èÊý¤ª¤è¤Óµ»½Ñ¡¢¸¶ÎÁ¡¦ÊäºÞ¤ÎͳÍ褪¤è¤ÓÉʼÁ´ð...

 
°åÎÅ´ï³£¤ª¤è¤ÓÀ½ÉÊ ¾Ü¤·¤¯

IEC¡Ê¹ñºÝÅŵ¤É¸½à²ñµÄ¡ËÊó¹ð¡¢¥ì¥ó¥È¥²¥óµ¡´ï¡¢Ä¶²»Çȵ¡´ï¡¢MRI¡¢CT¡¢¸ÆµÛµ¡¡¢·ì±Õ¾ô²½Íѵ¡...

 
¹ñºÝ²ñµÄƱ»þÄÌÌõ ¾Ü¤·¤¯

¹ñºÝ²ñµÄ¡¢¸¦µæƤÏÀ²ñ¡¢Ç¯²ñ²ñµÄ¤Î¸½¾ìÄÌÌõ¡¢Æ±»þÄÌÌõ¡¢±óµ÷Î¥²ñµÄËÝÌõ¡¢±ÇÁü»ñÎÁ¡¢Âç²ñµÄÆüÄøËÝÌõ¡¢...

À®¸ùÎã
SFDA
WHO(World Health
WHO(World Health
Novartis Pharma
Beijing Municipa
Bayer
Healthcare
Chinese Medical
Nycomed Pharma
 
 
·­Òë´Ê»ãÏÂÔØ
ҽѧ´Ê»ã
¡¡¡¤ Ò©Àíѧ ¡¡¡¤ Ò©Îﻯѧ´Ê»ã ¡¡¡¤ ÐÂÒ©±¨Åú´Ê»ã
Ò©Àíѧ
English
ÖÐÎÄ
English
ÖÐÎÄ
absorption
ÎüÊÕ£¬ÎüÊÕ×÷ÓÃ
kanamycin
¿¨ÄÇùËØ
abstinence syndrome
½ä¶ÏÖ¢×´
latent period
DZ·üÆÚ
acetaminophen
´×°±·Ó
laxative
кҩ
acute reaction
¼±ÐÔ·´Ó¦
lethal dose
ÖÂËÀÁ¿
addiction
³Éñ«ÐÔ
levodopa
×óÐý¶à°Í
adrenergic drug
ÉöÉÏÏÙËØÒ©
liability for abuse
ÀÄÓÃÇãÏò
adrenoceptor
ÉöÉÏÏÙÊÜÌå
lidocaine (xylocaine)
Àû¶à¿¨Òò
adrenoceptor blocking drug
ÉöÉÏÏÙËØÊÜÌå×è¶ÏÒ©
ligand
ÅäÌå
adrenocortical hormone
ÉöÉÏÏÙƤÖʼ¤ËØ
lincomycin
ÁÖ¿ÉùËØ
adrenomimetic drug
ÄâÉöÉÏÏÙËØÒ©
lithium carbonate
̼Ëáï®
affinity
Ç׺ÍÁ¦
loading dose
¸ººÉ¼ÁÁ¿
after effect
ºóÒÅЧӦ
lobeline
ɽ¹£²Ë¼î
agent
Ò©¼Á
local anaesthetics
¾ÖÂéÒ©
agonist
¼¤¶¯¼Á£¬Ð˷ܼÁ£¬Ö÷¶¯¼¡
magnesium sulfate
ÁòËáþ
aldosterone
È©¹Ìͪ
margin of safety
°²È«·¶Î§
allergy
±ä̬·´Ó¦
mechanism of action
×÷ÓûúÖÆ
aminoglycosides
°±»ùÌÇß°Àà
meclofenoxate
ÂÈõ¥ÐÑ
amitriptyline
°¢ÃÜÌæÁÖ
median effective dose
°ëÊýÓÐЧÁ¿
Amobarbital (amytal)
ÒìÎì°Í±ÈÍ×
meperidine (pethidine)
ßßÌæà¤
amoxicillin
ôÇ°±ÜÐÇàùËØ(°¢ÄªÎ÷ÁÖ)
metabolism
г´úл
amphotericin B
¶þÐÔùËØB
metabolite
´úлÎï
ampicillin
°±ÜÐÇàùËØ(°¢±ÈÎ÷ÁÖ)
metaraminol
¼äôÇ°·
amrinone
°·ßÁͪ
metformin
¶þ¼×Ë«ëÒ
anaesthetic ether
Âé×íÒÒÃÑ
methadone
ÃÀɳͪ
analgesia
ÕòÍ´
methimazole
¼×Áòßäßò
analgesics
ÕòÍ´Ò©
methyldopa
¼×»ù¶à°Í
angiotensin converting
Ѫ¹Ü½ôÕÅËØת»»
methylphenidate
ßß´×¼×õ¥
anisodamine
ɽݹÝмî
metoprolol
ÃÀÍÐÂå¶û
antagonist
Þ׿¹¼Á
metronidazole
¼×Ïõßò(ÃðµÎÁé)
antiadrenergic drug
¿¹ÉöÉÏÏÙËØ
mexiletine
ÃÀÎ÷ÂÉ
antianginal drug
¿¹ÐĽÊÍ´Ò©
minimal effective dose
×îСÓÐЧÁ¿
antianxiety
¿¹½¹ÂÇ
minimal toxic dose
×îСÖж¾Á¿
antiasthmatic drug
¿¹´­Ò©
molecular pharmacology
·Ö×ÓÒ©Àíѧ
antibiotics
¿¹ÉúËØ
monoamine oxidase (MAO)
µ¥°·Ñõ»¯Ã¸
anticarcinoma drug
¿¹Ö×ÁöÒ©
morphine
Âð·È
anticholinergic drug
¿¹µ¨¼îÒ©
muscarine
¶¾Þ¦¼î
anticholinesterase drug
¿¹µ¨¼îõ¥Ã¸Ò©
nalorphine
±ûÏ©Âð·È
anticoagulant
¿¹ÄýѪҩ
naloxone
ÄÉÂåͪ
anticonvulsive drug
¿¹¾ªØÊÒ©
negative chronotropic action
¸ºÐÔ±äʱЧӦ
antidiabetic drug
¿¹ÌÇÄò²¡Ò©
Neostigmine
ÐÂ˹µÄÃ÷
antidiarrheal agent
ֹкҩ
neuroleptanalgesia
Éñ¾­°²¶¨ÕòÍ´Êõ
antiepileptic drug
¿¹ñ²ðïÒ©
neuroleptic drug
Éñ¾­°²¶¨Ò©
antihypertensive drug
¿¹¸ßѪѹҩ
neuromuscular blocking drug
Éñ¾­¼¡Èâ×è¶ÏÒ©
antiinflammatory agent
¿¹Ñ×Ò©
neuropharmacology
Éñ¾­Ò©Àíѧ
antimalarial drug
¿¹Å±Ò©
nicardipine
ÄῨµØƽ
antimanic drug
¿¹Ôê¿ñÒ©
nicotine
Ñ̼î
antituberculosis drug
¿¹½áºËÒ©
nifidipine
Ïõ±½µØƽ
artemisinin
ÇàÝïËØ
nimodipine
ÄáĪµØƽ
aspirin
°¢Ë¹Æ¥ÁÖ
nitrendipine
ÄáȺµØƽ
atenolol
°¢ÌæÂå¶û
nitroglycerin
ÏõËá¸ÊÓÍ
atropine
°¢ÍÐÆ·
nitrous oxide
Ò»Ñõ»¯Ñǵª(ЦÆø)
barbiturates
°Í±ÈÍ×Àà
noradrenaline (norepinephrine)
È¥¼×ÉöÉÏÏÙËØ
basis pharmacology
»ù´¡Ò©Àíѧ
novocaine
Å«·ð¿¨Òò
benzodiazepines
±½¶þµª
occupation theory
Õ¼Áìѧ˵
biguanides
Ë«ëÒÀàÒ©Îï
one compartment model
Ò»ÊÒÄ£ÐÍ
bioavailability
ÉúÎïÀûÓöÈ
oxidation
Ñõ»¯
biochemical pharmacology
Éú»¯Ò©Àíѧ
parenteral route
·Ç³¦µÀ;¾¶
biotransformation
ÉúÎïת»¯
partial agonist
²¿·Ö¼¤¶¯¼Á
bretylium
äåÜа·
partial antagonist
²¿·ÖÞ׿¹¼Á
bromocriptine
äåÒþͤ
peak time
·åʱ¼ä
bumetanide
²¼ÃÀËûÄᣬ¶¡±½ÑõËá
penicillin G (benzylpenicillin)
ÇàùËØG(ÜÐÇàùËØ)
caffeine
¿§·ÈÒò
pentazocine
ÕòÍ´ÐÂ
calcium antagonists
¸ÆÞ׿¹Ò©
per os
¿Ú·þ
carbamazepine
¿¨°ÍÎ÷ƽ
perphenazine
·ÜÄ˾²
carbenicillin
ôÈÜÐÇàùËØ
persistent period
³ÖÐøʱ¼ä
carbidopa
¿¨±È¶à°Í
pharmacodynamics
Ò©£¨ÎЧ£¨Ó¦£©¶¯Á¦Ñ§
carbimazole
¿¨±ÈÂíßò
pharmacokinetics
Ò©£¨Î´ú£¨Ð»£©¶¯Á¦Ñ§
carcinogenicity
Ö°©Á¦
pharmacology
Ò©Àíѧ
cardiac glycoside
Ç¿ÐÄß°
pharmacology
Ò©Àíѧ
cardiovascular pharmacology
ÐÄѪ¹ÜÒ©Àíѧ
pharmacopeia
񩵊
carrier
Я´øÕߣ¬ÔØÌ壬ÔØÁ÷×Ó£¬´ø³æÕß
phenobarbital (luminal)
±½°Í±ÈÍ×(³Ã×ÄÇ)
catecholamine
¶ù²è·Ó°·
phenolphthalein
·Ó̪
central stimulant
ÖÐÊàÐË·ÜÒ©
phenothiazines
·ÔàçàºÀà
depression
ÒÖÖÆ£¬¼õѹ
phenoxybenzamine
·ÓÜÐÃ÷
detoxification
½â¶¾£¬½â¶¾×÷ÓÃ
phentolamine
·ÓÍ×À­Ã÷
dexamethasone
µØÈûÃ×ËÉ
physostigmine
¶¾±â¶¹¼î
diazepam
°²¶¨
pilocarpine
ë¹ûÔÆÏã¼î
diazoxide
¶þµªàº
pindolol
ßÅßáÂå¶û
dicaine
µÄ¿¨Òò
placebo
°²Î¿¼Á
dicoumarol
Ë«Ï㶹ËØ
placental barrier
Ì¥ÅÌÆÁÕÏ
digestants
ÖúÏû»¯Ò©
polymyxins
¶àÕ³¾úËØÀà
digitalis
ÑóµØ»Æ
positive inotropic action
ÕýÐÔ±äÁ¦Ð§Ó¦
digitoxin
ÑóµØ»Æ¶¾ß°
pralidoxime chloride
ÂȽâÁ׶¨
digoxin
µØ¸ßÐÁ
pralidoxime iodide
µâ½âÁ׶¨
diphenhydromine benadryl
±½º£À­Ã÷
prednisolone
ÆÃÄáËÉÁú
diuretic
ÀûÄò¼Á
prednisone
ÆÃÄáËÉ
dobutamine
¶à°Í·Ó¶¡°·
probenecid
±û»ÇÊæ
dosage
¼ÁÁ¿
procainamide
ÆÕ³¿¨Òò°·
droperidol
·úßßÀû¶à
promethazine
Òì±ûàº
drug abuse
Ò©ÎïÀÄÓÃ
propafenone
ÆÕÂÞÅÁͪ
drug dependence
Ò©ÎïÒÀÀµÐÔ
propranolol
Ðĵð²
drug enzyme
ҩø
propylthiouracil
±û»ùÁòÑõà×à¤
drug metabolism
Ò©Îï´úл
protein binding
µ°°×½áºÏ
efferent nervous system
´«³öÉñ¾­ÏµÍ³
psychopharmacology
¾«ÉñÒ©Àíѧ
efficacy
ЧÄÜ
psychotroptic drug
¿¹¾«Éñ²¡Ò©
elimination rate constant
Çå³ýËÙÂʳ£Êý
pyrimethamine
ÒÒ°·à×à¤
ephedrine
Âé»Æ¼î
quinidine
¿üÄᶡ
ethambutol
ÒÒ°·¶¡´¼
quinine
¿üÄþ
ethosuximide
ÒÒçú°·
quinolones
à­ÅµÍªÀà
etiological treatment
²¡ÒòÖÎÁÆ
ranitidine
À×ÄáÌ涡
euphoria
ÐÀ¿ìÖ¢
receptor
ÊÜÌå
excitation
¼¤·¢£¬ÐË·Ü
rectum
Ö±³¦
excretion
·ÖÃÚ£¬ÅÅй
replacement therapy
Ìæ´úÖÎÁÆ
fentanyl
·ÒÌ«Äá
reserpine
ÀûѪƽ
first pass effect
Ê×¹ýЧӦ
residual period
²ÐÁôÆÚ
first pass elimination
Ê×¹ýÏû³ý
resistance
ÄÍÒ©ÐÔ£¬×èÁ¦
fluphenazine
·ú·ÜÄ˾²
salbutamol
ɳ¶¡°·´¼
folic acid
Ò¶Ëá
scopolamine
¶«Ý¹Ýмî
furazolidone
ß»à«ßòͪ
secobarbital (seconal)
˾¿É°Í±ÈÍ×(ËÙ¿ÉÃß)
furosemide
ËÙÄò
secondary reaction
¼Ì·¢·´Ó¦
ganglionic blocking drug
Éñ¾­½Ú×è¶ÏÒ©
sedatives
Õò¾²Ò©
gentamicin
Çì´óùËØ
selectivity
Ñ¡ÔñÐÔ
glucocorticoid
ÌÇƤÖʼ¤ËØ
side reaction
¸±×÷ÓÃ
gray baby syndrome
»ÒÓ¤×ÛºÏÕ÷
site of metabolism
´úл²¿Î»
Guanethidine
ëÒÒÒà¤
skeletal muscular relaxant
¹Ç÷À¼¡ËɳÚÒ©
habituation
Ï°¹ßÐÔ
sodium cromoglycate
É«¸ÊËá¶þÄÆ
halothane
·úÍé
sodium nitroprusside
ÏõÆÕÄÆ
hepatoenteral circulation
¸Î³¦Ñ­»·
sodium thiopental
ÁòÅçÍ×ÄÆ
heroin
º£ÂåÒò
sodium valproate
±ûÎìËáÄÆ
histamine
×é°·
spiramycin
ÂÝÐýùËØ
Homatropine
ºóÂíÍÐÆ·
stimulation
´Ì¼¤
hydrochlorothiazide
ÇâÂÈàçàº
streptokinase
Á´¼¤Ã¸
hydrocortisone
Ç⻯¿ÉµÄËÉ
structure activity relationship
¹¹Ð§¹Øϵ
hydrolazine
ëÂÇüàº
succinylcholine
çúç굨¼î
hydroprednisone
Ç⻯ÆÃÄáËÉ
sulfonylureas
»Çõ£ëåÀàÒ©Îï
hyperreaction
¸ßÃôÐÔ
supplement therapy
²¹³äÖÎÁÆ
hypersensitive reaction
¹ýÃô·´Ó¦
symptomatic treatment
¶ÔÖ¢ÖÎÁÆ
Ibuprofen
²¼Âå·Ò
terbutaline
Ìز¼ËûÁÖ
idiosyncratic reaction
ÌØÒìÖÊ·´Ó¦
terramycin
ÍÁùËØ
imipramine
±ûßäàº
tetracaine
¶¡¿¨Òò
immunopharmacology
ÃâÒßÒ©Àíѧ
tetracycline
ËÄ»·ËØ
immunopotentiating drug
ÃâÒßÔöÇ¿Ò©
therapeutic action
ÖÎÁÆ×÷ÓÃ
immunosuppressive drug
ÃâÒßÒÖÖÆÒ©
therapeutic dose
ÖÎÁÆÁ¿
indomethacin
ßÅßáÃÀÐÁ£¬ÏûÑ×Í´
therapeutic index
ÖÎÁÆÖ¸Êý
inhalation
ÎüÈë
thiazides
àçàºÀà
inhibition
ÒÖÖÆ
threshold dose
ãмÁÁ¿
insulin
ÒȵºËØ
tolbutamide
¼×»Ç¶¡ëå
intrinsic activity
ÄÚÔÚ»îÐÔ
tolerance
ÄÍÊÜ
iodide
µâ»¯Îï
 
 
 
©

2004-2019Ë̵þ°ÉÎÓ°åÌôËÝÌõ¥»¥ó¥¿¡¼